Abstract
The value of serological testing to inform the public health response to the SARS-CoV-2 pandemic is debated. Using a transmission model, we examined how serology can be implemented to allow seropositive individuals to resume more normal levels of social interaction while offsetting the risks. We simulated the use of widespread serological testing with realistic assay characteristics, in which seropositive individuals partially restore their social contacts and act as immunological ‘shields’. If social distancing is relaxed by 50% at the same time that quarterly serological screening is initiated, approximately 120,000 deaths could be averted and a quarter of the US population could be released from social distancing in the first year of the epidemic, compared to a scenario without serological testing. This strategy has the potential to substantially flatten the COVID-19 epidemic curve while also allowing a substantial number of individuals to safely return to social and economic interactions.
One Sentence Summary Informing relaxation of social distancing with serological testing can reduce population risk while offsetting some of the severe social and economic costs of a sustained shutdown.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
BAL and ANMK were supported by the Vaccine Impact Modeling Consortium; BAL and KNN were supported by NIH/NICHD R01 HD097175; BAL, KNN, and ANMK were supported by NIH/NIGMS R01 GM124280; JSW was supported by Simons Foundation (SCOPE Award ID 329108); JSW and CZ were supported by the Army Research Office (W911NF1910384); JSW was supported by NIH (1R01AI46592-01); JSW was supported by National Science Foundation (1806606 and 1829636).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Transmission model code and incidence data used are available at the links provided
https://coronavirus.jhu.edu/map.html
https://github.com/lopmanlab/Serological_Shielding
